- PureTech Health noted that affiliate company Vedanta Biosciences had entered into a collaboration with Bristol-Myers Squibb.

The companies had agreed to to evaluate Vedanta's microbiome-derived immuno-oncology candidate, VE800, in combination with Bristol Myers-Squibb's programmed death-1 immune checkpoint inhibitor Opdivo, in patients with advanced or metastatic cancers.

Under the terms of the agreement, Vedanta Biosciences would maintain control of its VE800 programme, including global R&D and commercial rights.

'There is growing evidence to support the role of the microbiome across a range of immune-mediated diseases, including cancers,' Puretech chief of business and strategy Bharatt Chowrira said.

'We are pleased to be working with Bristol-Myers Squibb to explore VE800 in combination with Opdivo as a potential treatment option for patients with advanced or metastatic cancers.'

At 9:15am: [LON:PRTC] PureTech Health Plc share price was +3.5p at 183.5p

Story provided by